-
1.发明申请公开(公告)号：US20060003931A1
公开(公告)日：2006-01-05
申请号：US11124635
申请日：2005-05-06
IPC分类号： A61K38/18 , G06F19/00 , C07K14/475
CPC分类号： C07K14/4753 , C07K2299/00 , G16B15/00 , G16B20/00
摘要： The disclosure provides a crystal and crystal structure of the Hepatocyte Growth Factor Beta (HGF β) Chain, as well as use of the crystal structure in the design, identification, and selection of modulators of HGF or Met activity.
摘要翻译： 本公开提供了肝细胞生长因子β（HGFβ）链的晶体和晶体结构，以及在HGF或Met活性调节剂的设计，鉴定和选择中使用晶体结构。
-
2.发明申请公开(公告)号：US20060177446A1
公开(公告)日：2006-08-10
申请号：US11290770
申请日：2005-11-29
IPC分类号： A61K39/395 , C07K16/22
CPC分类号： C07K16/4258 , C07K16/4241 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies and polypeptides useful in blocking the binding of antibodies to anti-tissue factor, decreasing the activity of the anti-tissue factor antibodies and/or neutralizing the activity of an anti-tissue factor antibody. The present invention also relates to nucleic acids encoding the antibodies and polypeptides and compositions comprising the antibodies or polypeptides or nucleic acid molecules. The present invention provides methods of treating a hypercoagulable state or an inflammatory disease using the antibodies and polypeptides of this invention and other methods of using said antibodies and polypeptides.
摘要翻译： 本发明涉及可用于阻断抗体与抗组织因子结合的抗体和多肽，降低抗组织因子抗体的活性和/或中和抗组织因子抗体的活性。 本发明还涉及编码抗体和多肽的核酸以及包含抗体或多肽或核酸分子的组合物。 本发明提供使用本发明的抗体和多肽以及使用所述抗体和多肽的其它方法治疗高凝状态或炎性疾病的方法。
-
公开(公告)号：US20060019893A1
公开(公告)日：2006-01-26
申请号：US11159647
申请日：2005-06-23
申请人： Henry Maun , Charles Eigenbrot , Robert Lazarus
发明人： Henry Maun , Charles Eigenbrot , Robert Lazarus
IPC分类号： C07K14/755
CPC分类号： C12N9/6437 , C12Y304/21021
摘要： Novel compounds are provided which modulate a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention are variants of Factor VIIa (FVIIa). Pharmaceutical compositions are also provided which comprise the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
摘要翻译： 提供了新的化合物，其调节FVIIa介导的或相关联的过程或事件，例如将FX转化为FXa，FVII至FVIIa或FIX至FIXa。 在具体方面，本发明的化合物是因子VIIa（FVIIa）的变体。 还提供了包含新化合物以及它们在诊断，治疗和预防方法中的用途的药物组合物。
-
公开(公告)号：US20070092940A1
公开(公告)日：2007-04-26
申请号：US11233258
申请日：2005-09-22
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗体 - 药物共轭物： in-line-formula description =“In-line Formulas”end =“lead”？> Ab-（LD）
I <？in-line-formula description =“In-line Formulas”end =“尾”→其中p为1至4.公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。
-
公开(公告)号：US07084109B2
公开(公告)日：2006-08-01
申请号：US10202915
申请日：2002-07-25
CPC分类号： C07K7/08 , A61K38/00 , Y10S514/824
摘要： This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
-
-
-
-
搜索结果
5 条记录 (耗时 0.04 秒)
